Foteini Vasilopoulou
UCL Queen Square Institute Of Neurology
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 06, 2025
Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates as Imidazoline I2 Receptor Ligands with Anti-Alzheimer and Analgesic Properties.
Journal: Journal of medicinal chemistry
Published: January 17, 2025
Editorial: Extracellular vesicles: emerging roles in the aged and neurodegenerative brain.
Journal: Frontiers in cellular neuroscience
Published: November 04, 2024
Cognitive Decline and BPSD Are Concomitant with Autophagic and Synaptic Deficits Associated with G9a Alterations in Aged SAMP8 Mice.
Journal: Cells
Published: July 12, 2022
Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease.
Journal: European journal of medicinal chemistry
Published: February 23, 2021
Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil.
Journal: British journal of pharmacology
Published: December 17, 2020
Correction to Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease.
Journal: Journal of medicinal chemistry
Published: September 14, 2020
Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes after Treatment with I2-Imidazoline Receptor Ligand MCR5.
Journal: Pharmaceutics
Published: April 24, 2020
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease.
Journal: Journal of medicinal chemistry
Published: March 10, 2020
Last Updated: 09/26/2026